Azelaic Acid: The Cosmetic and Drug Boundary in Canada

Azelaic acid shows up in a lot of maker formulas right now, usually chasing the same skin-clarity trend that made it popular in dermatology offices. What doesn't always come with the trend is a clear sense of when it's fine to sell as a cosmetic in Canada and when you've quietly crossed into drug territory.

The basics: INCI and CAS

On a Canadian ingredient declaration, azelaic acid is listed by its INCI name, Azelaic Acid, and its CAS number is 123-99-9. That CAS number is worth writing down if you're sourcing from more than one supplier, because it's the one constant across different trade names and blend formulations. A supplier might sell it to you as part of a proprietary "brightening complex," but the CNF still needs the actual INCI name and the real concentration in your finished product, not the trade name of the blend.

If azelaic acid arrives to you inside a supplier blend, say a complex that's 15% azelaic acid in a carrier, you multiply that 15% by however much of the blend you use in your formula to get the true finished-product concentration. That's the number that goes on the notification, not the blend's own labeled percentage.

Where the line sits

Azelaic acid itself isn't inherently a drug ingredient. What pushes a product from cosmetic to drug is usually a combination of concentration and the claim you make. In Canada, a product is generally treated as a cosmetic when:

• It's used for a cosmetic purpose, meaning cleansing, improving appearance, or altering odor, not treating or preventing a disease.
• The claims on the label and marketing stay in cosmetic language: brightening, evening skin tone, smoothing texture.

It moves toward drug territory when:

• The claim becomes therapeutic, such as "treats acne," "clears acne lesions," or references a diagnosed skin condition.
• The concentration and formulation are positioned as delivering a medical-grade outcome rather than a cosmetic one.

This is the same logic that applies across a lot of active ingredients used at both cosmetic and pharmaceutical strength: the ingredient doesn't have a hard legal switch built into its molecule, the switch is in the claim and the regulatory frame the product is sold under.

Why this trips people up

A lot of makers get comfortable with the ingredient because they've seen dermatology brands market 15 to 20 percent azelaic acid formulations as legitimate acne treatments. What's easy to miss is that those dermatology products are usually filed and sold as drugs, with the substantiation and regulatory pathway that comes with a therapeutic claim. Copying the concentration without copying the drug filing, while still making an acne-treatment claim, is where a product ends up misclassified.

If your product is styled as a gentle exfoliating or brightening serum, sold with cosmetic-purpose language, and filed as a cosmetic on a CNF, that's a defensible cosmetic position. If your marketing starts saying it treats or clears acne, you've made a drug claim regardless of what the label calls the product.

Practical checklist before you file

1. Confirm the actual finished-product concentration of azelaic acid, accounting for any supplier blend dilution.
2. Read your own marketing copy and product description as if you were a regulator. Look for words like "treat," "cure," "clear acne," or references to a medical condition.
3. Decide if your positioning is cosmetic (appearance, texture, brightening) or therapeutic (treating a condition). If it's the latter, you're likely in drug territory and need a different regulatory pathway entirely, not a CNF.
4. List azelaic acid by its INCI name and CAS 123-99-9 alongside the rest of your ingredients on the Cosmetic Notification Form, with the correct finished concentration.

A note on the fragrance allergen changes

If your azelaic acid product also carries fragrance, keep the incoming allergen disclosure dates in mind separately. List 1 fragrance allergens become mandatory on the CNF and label on April 12, 2026, and List 2 follows on August 1, 2026. That's a separate compliance track from the azelaic acid claim question, but it's easy to be tracking one and forget the other when you're updating a formula.

Getting the INCI name, the real concentration, and the claim language aligned before you file is most of the work here. Cosmetic Comply's ingredient matching handles the INCI and CAS mapping and expands supplier blends into true percentages automatically, which at least takes the arithmetic part of this off your plate while you sort out the claim itself.